Open Access

Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer (Review)

  • Authors:
    • Kimberly A. Silverio
    • Shyam A. Patel
  • View Affiliations

  • Published online on: February 13, 2017     https://doi.org/10.3892/ol.2017.5721
  • Pages: 2015-2020
  • Copyright: © Silverio et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The advent of immunotherapy for cancer has contributed to the era of personalized medicine for cancer. The various immunotherapy‑based treatments that have been explored thus far include monoclonal antibody therapy, tumor vaccines, immune checkpoint blockade and adoptive T cell transfer, among others. The groundwork for all these immunotherapeutic modalities rests within the tumor microenvironment, specifically the immune factors that influence the tumor‑drug interface. Prior to therapeutic design, the tumor microenvironmental interactions and the current barriers to successful treatment must first be understood. In the present review, it is proposed that cancer cell eradication within the tumor niche may be achieved by reprogramming of the immune microenvironment in favor of a pro‑inflammatory antitumor profile at an early stage. This pro‑inflammatory profile may, in turn, be influenced by tumor recall antigens, which function to stimulate the cell‑mediated or humoral responses involved in antitumor immunity. These measures serve to counteract the immunotolerant state of the tumor microenvironment. Such measures are critical to therapeutic successes.

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Silverio KA and Silverio KA: Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer (Review). Oncol Lett 13: 2015-2020, 2017
APA
Silverio, K.A., & Silverio, K.A. (2017). Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer (Review). Oncology Letters, 13, 2015-2020. https://doi.org/10.3892/ol.2017.5721
MLA
Silverio, K. A., Patel, S. A."Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer (Review)". Oncology Letters 13.4 (2017): 2015-2020.
Chicago
Silverio, K. A., Patel, S. A."Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer (Review)". Oncology Letters 13, no. 4 (2017): 2015-2020. https://doi.org/10.3892/ol.2017.5721